AZ/Merck & Co reveal data supporting PARP drug in prostate cancer

PARP drugs work by interfering with cancer cells’ DNA repair system, eventually causing them to self-destruct – and AstraZeneca and Merck & Co’s Lynparza (olaparib) was the trailblazer in this drug class after first approval in ovarian cancer in 2014.

But since then the drug has gone on to be approved in breast cancer, and it looks possible that prostate cancer could be another use.